Stock analysis · Bull Rankings model

TNDM analysis

Tandem Diabetes Care IncHealth Care. Scored on the same transparent 7-signal model behind the daily rankings.

TNDM
Tandem Diabetes Care Inc · Health Care
FCF-$4mF
Rev+4.5%C+
D/E0.87B
P/S1.0xA-
PEG
59Score
$14.82
1Y Target$20.01Near-term target
5Y Target$29.81Compound horizon
10Y Target$77.57Long-dated conviction
FCF-$4mTTM · 03/26
F
FCF is negative (-$4m) — cash-burning phase; acceptable only for pre-profit spec names · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+4.5%TTM YoY
C+
Revenue +4.5% — steady but below market-beating range · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.87total
B
D/E 0.87 — at market average, manageable · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/S1.0x
A-
P/S 1.0x — cheap for any tech/growth name
PEGproxy
PEG not meaningful — earnings growth negative or data unavailable · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Health Care · market cap $996m. Down 50% from 52-week high of $29.65 — deep drawdown territory.
Moat
Speculative bucket — the moat thesis is forward-looking; without proven margin structure or capital efficiency yet, the durability argument is about IP / network effects / first-mover position that the company hasn't fully monetized.
Risk
Free cash flow is negative (-$4m) — capital raises or debt issuance likely required; dilution / leverage risk. Currently unprofitable (margin -9.2%) — path to GAAP profitability is the core thesis risk. Down 50% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon
1-3 yr $20.01 (structural (no analyst coverage)) — catalyst-driven; binary events dominate. 5 yr $29.81 — requires the platform / technology to reach commercial scale. 10 yr $77.57 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Shares to buy
134
Position size
$1,986
4.0% of portfolio
Stop price
$11.12
25% below $14.82
$ at risk
$500.00
1% of portfolio

Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.

Analyze another ticker →